JasmyCoin (JASMY) saw a price increase on October 1, with reported gains ranging from about 10% to 14% depending on the data source. However, discrepancies between market tables and unclear timing of derivatives data make it difficult to confirm the exact size of the rally or the conviction of investors behind it. Metrics like open interest and spot-selling volumes were discussed but lacked clear context, so they do not definitively reveal trader positions or sentiment. JasmyCoin is an Ethereum-based token linked to IoT platforms by Jasmy Incorporated.
JasmyCoin's price rose on October 1 with reported gains between 10% and 14%, though market data discrepancies make the exact rally size unclear. For readers following cryptocurrency markets, here is Pluang's snapshot as of Oct 02, 2026 03:52 WIB: out of 50 major cryptocurrencies priced on Pluang, 32 rose and 17 fell. Notable movers include SAND at Rp797 (+2.92%, 76% Sell / 24% Buy), THETA at Rp3.930 (-2.92%, 31% Sell / 69% Buy), and UNI at Rp163.383 (+2.91%, 93% Sell / 7% Buy).
Wells Fargo initiated coverage on BlackRock with an 'Overweight' rating, highlighting it as a good entry point for investors. Analysts expect BlackRock's Q3 earnings per share to rise to $14.25 from $11.55 a year ago, with revenue projected at $7.56 ...
Nike reported earnings per share of $0.48, beating estimates, but revenue fell short at $11.21 billion due to weak demand in Greater China and rising competition. The company issued a cautious fiscal 2027 outlook with EPS forecast between $1.15 and $...
NETSOL Technologies reported a record $20.7 million revenue in fiscal 2026 Q4, with net income rising 45.9% to $3.8 million. The company improved its gross margin to 63.6% and operating margin to 21.6%, reflecting enhanced profitability. For fiscal 2...
On October 1, 2026, Nexalin Technology surged 76.4% after securing a 10-year exclusive deal for its medical device in South America. Armada Acquisition Corp. II jumped 42.9% following shareholder approval of its merger with Evernorth, expected to clo...
Jefferies analyst Roger Song set a $150 price target for Nektar Therapeutics, suggesting a 219% upside from its $46.99 trading price. This comes after Nektar presented positive six-month Phase IIb trial results for its alopecia drug REZPEG, which als...
